|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pecorelli S: Revised FIGO staging for
carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol
Obstet. 105:103–104. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Japan Society of Gynecologic Oncology
(eds), . Formulation Committee of the Treatment Guidelines for
Cervical Cancer. Kanehara & Co.; Tokyo: 2011, (In
Japanese).
|
|
4
|
National Comprehensive Cancer Network
(NCCN), . NCCN Clinical Practice Guidelines in Oncology: Cervical
Cancer. Version II. NCCN; Fort Washington, PA: 2013
|
|
5
|
Morris M, Eifel PJ, Lu J, Grigsby PW,
Levenback C, Stevens RE, Rotman M, Gershenson DM and Mutch DG:
Pelvic radiation with concurrent chemotherapy compared with pelvic
and para-aortic radiation for high-risk cervical cancer. N Engl J
Med. 340:1137–1143. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Eifel PJ, Winter K, Morris M, Levenback C,
Grigsby PW, Cooper J, Rotman M, Gershenson D and Mutch DG: Pelvic
irradiation with concurrent chemotherapy versus pelvic and
para-aortic irradiation for high-risk cervical cancer: An update of
radiation therapy oncology group trial (RTOG) 90–01. J Clin Oncol.
22:872–880. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ishiko O, Sumi T, Yasui T, Matsumoto Y,
Kawamura N, Ogita S, Kamino T, Nakamura K and Yamada R:
Balloon-occluded arterial infusion chemotherapy, simple total
hysterectomy and radiotherapy as a useful combination-therapy for
advanced cancer of the uterine cervix. Oncol Rep. 7:141–144.
2000.PubMed/NCBI
|
|
8
|
Souhami L, Gil RA, Allan SE, Canary PC,
Araújo CM, Pinto LH and Silveira TR: A randomized trial of
chemotherapy followed by pelvic radiation therapy in stage IIIB
carcinoma of the cervix. J Clin Oncol. 9:970–977. 1991.PubMed/NCBI
|
|
9
|
Tattersall MH, Lorvidhaya V, Vootiprux V,
Cheirsilpa A, Wong F, Azhar T, Lee HP, Kang SB, Manalo A, Yen MS,
et al: Randomized trial of epirubicin and cisplatin chemotherapy
followed by pelvic radiation in locally advanced cervical cancer.
Cervical cancer study group of the Asian Oceanian clinical oncology
association. J Clin Oncol. 13:444–451. 1995.PubMed/NCBI
|
|
10
|
Ishiko O, Sumi T, Yasui T, Matsumoto Y,
Ogita S, Kaminou T, Nakamura K and Yamada R: Tumor marker and MR
imaging criteria for evaluating the efficacy of cyclic
balloon-occluded arterial infusion for advanced cancer of the
uterine cervix. Oncol Rep. 7:827–830. 2000.PubMed/NCBI
|
|
11
|
Ishiko O, Sumi T, Yoshida H, Ogita S and
Yamada R: Expression of apoptosis regulatory proteins in advanced
cancer of the uterine cervix after cyclic balloon-occluded arterial
infusion chemotherapy. Int J Oncol. 18:1151–1155. 2001.PubMed/NCBI
|
|
12
|
Okamoto E, Sumi T, Misugi F, Nobeyama H,
Hattori K, Yoshida H, Matsumoto Y, Yasui T, Honda K and Ishiko O:
Expression of apoptosis-related proteins in advanced uterine
cervical cancer after balloon-occluded arterial infusion
chemotherapy as an indicator of the efficiency of this therapy. Int
J Mol Med. 15:41–47. 2005.PubMed/NCBI
|
|
13
|
Nobeyama H, Sumi T, Misugi F, Okamoto E,
Hattori K, Matsumoto Y, Yasui T, Honda K, Iwai K and Ishiko O:
Association of HPV infection with prognosis after neoadjuvant
chemotherapy in advanced uterine cervical cancer. Int J Mol Med.
14:101–105. 2004.PubMed/NCBI
|
|
14
|
Panici P Benedetti, Bellati F, Manci N,
Pernice M, Plotti F, Di Donato V, Calcagno M, Zullo MA, Muzii L and
Angioli R: Neoadjuvant chemotherapy followed by radical surgery in
patients affected by FIGO stage IVA cervical cancer. Ann Surg
Oncol. 14:2643–2648. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Parker LH, Schmidt M, Jin SW, Gray AM,
Beis D, Pham T, Frantz G, Palmieri S, Hillan K, Stainier DY, et al:
The endothelial-cell-derived secreted factor Egfl7 regulates
vascular tube formation. Nature. 428:754–758. 2014. View Article : Google Scholar
|
|
16
|
Soncin F, Mattot V, Lionneton F, Spruyt N,
Lepretre F, Begue A and Stehelin D: VE-statin, an endothelial
repressor of smooth muscle cell migration. EMBO J. 22:5700–5711.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Campagnolo L, Leahy A, Chitnis S,
Koschnick S, Fitch MJ, Fallon JT, Loskutoff D, Taubman MB and
Stuhlmann H: EGFL7 is a chemoattractant for endothelial cells and
is up-regulated in angiogenesis and arterial injury. Am J Pathol.
167:275–284. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Schmidt M, Paes K, De Mazière A, Smyczek
T, Yang S, Gray A, French D, Kasman I, Klumperman J, Rice DS and Ye
W: EGFL7 regulates the collective migration of endothelial cells by
restricting their spatial distribution. Development. 134:2913–2923.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Charpentier MS and Conlon FL: Cellular and
molecular mechanisms underlying blood vessel lumen formation.
Bioessays. 36:251–259. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Delfortrie S, Pinte S, Mattot V, Samson C,
Villain G, Caetano B, Lauridant-Philippin G, Baranzelli MC,
Bonneterre J, Trottein F, et al: Egfl7 promotes tumor escape from
immunity by repressing endothelial cell activation. Cancer Res.
71:7176–7186. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jain RK: Normalization of tumor
vasculature: An emerging concept in antiangiogenic therapy.
Science. 307:58–62. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fan C, Yang LY, Wu F, Tao YM, Liu LS,
Zhang JF, He YN, Tang LL, Chen GD and Guo L: The expression of
Egfl7 in human normal tissues and epithelial tumors. Int J Biol
Markers. 28:71–83. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Díaz R, Silva J, García JM, Lorenzo Y,
García V, Peña C, Rodríguez R, Muñoz C, García F, Bonilla F and
Domínguez G: Deregulated expression of miR-106a predicts survival
in human colon cancer patients. Genes Chromosomes Cancer.
47:794–802. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhou L, Li J, Zhao YP, Guo JC, Cui QC,
Zhou WX, Zhang TP, Wu WM, You L and Shu H: Prognostic significance
of epidermal growth factor-like domain 7 in pancreatic cancer.
Hepatobiliary Pancreat Dis Int. 13:523–528. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Oh J, Park SH, Lee TS, Oh HK, Choi JH and
Choi YS: High expression of epidermal growth factor-like domain 7
is correlated with poor differentiation and poor prognosis in
patients with epithelial ovarian cancer. J Gynecol Oncol.
25:334–341. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li JJ, Yang XM, Wang SH and Tang QL:
Prognostic role of epidermal growth factor-like domain 7 protein
expression in laryngeal squamous cell carcinoma. J Laryngol Otol.
125:1152–1157. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Luo BH, Xiong F, Wang JP, Li JH, Zhong M,
Liu QL, Luo GQ, Yang XJ, Xiao N and Xie B: Epidermal growth
factor-like domain-containing protein 7 (EGFL7) enhances EGF
receptor-AKT signaling, epithelial-mesenchymal transition, and
metastasis of gastric cancer cells. PLoS One. 9:e999222014.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Haslehurst AM, Koti M, Dharsee M, Nuin P,
Evans K, Geraci J, Childs T, Chen J, Li J, Weberpals J, et al: EMT
transcription factors snail and slug directly contribute to
cisplatin resistance in ovarian cancer. BMC Cancer. 12:912012.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Işeri OD, Kars MD, Arpaci F, Atalay C, Pak
I and Gündüz U: Drug resistant MCF-7 cells exhibit
epithelial-mesenchymal transition gene expression pattern. Biomed
Pharmacother. 65:40–45. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Helleman J, Smid M, Jansen MP, van der
Burg ME and Berns EM: Pathway analysis of gene lists associated
with platinum-based chemotherapy resistance in ovarian cancer: The
big picture. Gynecol Oncol. 117:170–176. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chang TH, Tsai MF, Su KY, Wu SG, Huang CP,
Yu SL, Yu YL, Lan CC, Yang CH, Lin SB, et al: Slug confers
resistance to the epidermal growth factor receptor tyrosine kinase
inhibitor. Am J Respir Crit Care Med. 183:1071–1079. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
McConkey DJ, Choi W, Marquis L, Martin F,
Williams MB, Shah J, Svatek R, Das A, Adam L, Kamat A, et al: Role
of epithelial-to-mesenchymal transition (EMT) in drug sensitivity
and metastasis in bladder cancer. Cancer Metastasis Rev.
28:335–344. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Vega S, Morales AV, Ocaña OH, Valdés F,
Fabregat I and Nieto MA: Snail blocks the cell cycle and confers
resistance to cell death. Genes Dev. 18:1131–1143. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tsuji K, Yamada R, Kawabata M, Mitsuzane
K, Sato M, Iwahashi M, Kitayama S and Nakano R: Effect of balloon
occluded arterial infusion of anticancer drugs on the prognosis of
cervical cancer treated with radiation therapy. Int J Radiat Oncol
Biol Phys. 32:1337–1345. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sironi S, Belloni C, Taccagni G and
DelMaschio A: Invasive cervical carcinoma: MR imaging after
preoperative chemotherapy. Radiology. 180:719–722. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kim KH, Lee BH, Do YS, Chin SY, Park SY,
Kim BG and Jang JJ: Stage IIb cervical carcinoma: MR evaluation of
effect of intraarterial chemotherapy. Radiology. 192:61–65. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Sinicrope FA, Ruan SB, Cleary KR, Stephens
LC, Lee JJ and Levin B: bcl-2 and p53 oncoprotein expression during
colorectal tumorigenesis. Cancer Res. 55:237–241. 1995.PubMed/NCBI
|
|
38
|
Morishita M, Sumi T, Nakano Y, Teramae M,
Fukuda T, Nobeyama H, Yoshida H, Matsumoto Y, Yasui T and Ishiko O:
Expression of mitotic-arrest deficiency 2 predicts the efficacy of
neoadjuvant chemotherapy for locally advanced uterine cervical
cancer. Exp Ther Med. 3:341–346. 2012.PubMed/NCBI
|
|
39
|
Teramae M, Fukuda T, Wada T, Kawanishi M,
Imai K, Yamauchi M, Yasui T and Sumi T: Sirtuin1 expression
predicts the efficacy of neoadjuvant chemotherapy for locally
advanced uterine cervical cancer. Mol Clin Oncol. 3:73–78.
2015.PubMed/NCBI
|
